Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 126

Sort by

Sort Order Select

Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Blood (2024) 143 (4): 336–341.

https://doi.org/10.1182/blood.2023021579

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 status and impact on AML prognosis within the ELN 2022 risk classification

Shaun Fleming, Xavier Cheng-Hong Tsai, Rhiannon Morris, Hsin-An Hou, Andrew H. Wei

Blood (2023) 142 (23): 2029–2033.

https://doi.org/10.1182/blood.2023020855

Published: 2023

Includes: Supplemental data

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Blood (2023) 142 (23): 1960–1971.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial

Blood (2023) 142 (Supplement 1): 702.

https://doi.org/10.1182/blood-2023-180720

Published: 2023

Journal Articles

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Ing Soo Tiong, Tamia Nguyen, Charis Teh, Chong Chyn Chua, Sarah Ftouni, Thomas E Lew, Fiona C. Brown, Donia Moujalled, Christine Muttiah, Daniel Gray, Mary Ann Anderson, Philip A. Thompson, Constantine S. Tam, John F. Seymour, Sarah-Jane Dawson, Andrew H. Wei, Geoffrey Lindeman, Piers Blombery

Blood (2023) 142 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2023-180386

Published: 2023

Journal Articles

Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated

Blood (2023) 142 (Supplement 1): 973.

https://doi.org/10.1182/blood-2023-177929

Published: 2023

Journal Articles

Direct, Potent, and TP53-Independent Activity of Sting Agonists Against Acute Myeloid Leukaemia Enhances Venetoclax Efficacy In Vivo

Yin Yuan, Sarah T Diepstraten, Fiona C. Brown, Veronique Litalien, Andreas Strasser, Gemma L Kelly, Andrew W. Roberts, Andrew H. Wei

Blood (2023) 142 (Supplement 1): 4163.

https://doi.org/10.1182/blood-2023-179698

Published: 2023

Journal Articles

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Daniel Lopes De Menezes, Manuel Ugidos Guerrero, Arnaud Amzallag, Wendy L. See, Alberto Risueno, Charalampos Kyriakopoulos, Rajasekhar N.V.S. Suragani, Barry S. Skikne, C.L. Beach, Thomas Prebet, Maria Teresa Voso, Andre C. Schuh, Gail J. Roboz, Hartmut Döhner, Andrew H. Wei, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2023-187651

Published: 2023

Journal Articles

Pre-Transplant Measurable Residual Disease (MRD) Detection of KMT2A- rearranged Acute Myeloid Leukemia Is Strongly Associated with Inferior Post-Transplant Outcome

Sun Loo, Nicola Potter, Adam Ivey, Jenny O'Nions, Roderick Moon, Chun Yew Fong, Natasha Anstee, Ing Soo Tiong, Chong Chyn Chua, Jad Othman, Hannah Renshaw, Robert Baker, Nigel H. Russell, Ashish Bajel, Hsin-An Hou, Richard Dillon, Andrew H. Wei

Blood (2023) 142 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2023-185541

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Blood (2023) 142 (Supplement 1): 423.

https://doi.org/10.1182/blood-2023-185321

Published: 2023

Journal Articles

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Blood (2023) 141 (17): 2047–2061.

https://doi.org/10.1182/blood.2022018604

Published: 2023

Includes: Supplemental data

Journal Articles

Is BCL-xL the Achilles' heel of AEL and AMKL?

Fiona C. Brown, Andrew H. Wei

Blood (2023) 141 (13): 1505–1506.

https://doi.org/10.1182/blood.2022019246

Published: 2023

Journal Articles

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Blood (2023) 141 (6): 634–644.

https://doi.org/10.1182/blood.2022016090

Published: 2023

Includes: Supplemental data

Journal Articles

Revisiting coexisting chromosomal abnormalities in NPM1 -mutated AML in light of the revised ELN 2022 classification

Linus Angenendt, Christoph Röllig, Pau Montesinos, Farhad Ravandi, Gunnar Juliusson, Christian Récher, Raphaël Itzykson, Zdeněk Ráčil, Andrew H. Wei, Christoph Schliemann

Blood (2023) 141 (4): 433–435.

https://doi.org/10.1182/blood.2022018582

Published: 2023

Journal Articles

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Blood (2023) 141 (2): 156–167.

https://doi.org/10.1182/blood.2021014901

Published: 2023

Includes: Supplemental data

Journal Articles

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Blood (2022) 140 (25): 2754–2756.

https://doi.org/10.1182/blood.2022016963

Published: 2022

Includes: Supplemental data

Journal Articles

Pretransplant FLT3 -ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Blood (2022) 140 (22): 2407–2411.

https://doi.org/10.1182/blood.2022016567

Published: 2022

Includes: Supplemental data

Journal Articles

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Blood (2022) 140 (Supplement 1): 2033–2035.

https://doi.org/10.1182/blood-2022-159467

Published: 2022

Journal Articles

A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Amanda F. Cashen, Hongtao Liu, Monzr M. Al Malki, Joshua F. Zeidner, Matthew C. Foster, Angela Pannunzio, Brett Ramsey, Jan Baughman, John Muth, Ouiam Bakkacha, Eileen McNulty, Kenneth Jacobs, Jan K Davidson-Moncada, Andrew H Wei

Blood (2022) 140 (Supplement 1): 12740–12741.

https://doi.org/10.1182/blood-2022-158634

Published: 2022

NARROW

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

TP53 status and impact on AML prognosis within the ELN 2022 risk classification

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated

Direct, Potent, and TP53-Independent Activity of Sting Agonists Against Acute Myeloid Leukaemia Enhances Venetoclax Efficacy In Vivo

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Pre-Transplant Measurable Residual Disease (MRD) Detection of KMT2A- rearranged Acute Myeloid Leukemia Is Strongly Associated with Inferior Post-Transplant Outcome

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Is BCL-xL the Achilles' heel of AEL and AMKL?

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Revisiting coexisting chromosomal abnormalities in NPM1 -mutated AML in light of the revised ELN 2022 classification

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Pretransplant FLT3 -ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only